The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2012Bay Area Solvent Study - Symptoms (BASS-S)
Objective/Rationale:
Chlorinated solvents are commonly used in a variety of occupations. The solvents trichloroethylene (TCE) and perchloroethylene (PERC) have been associated with an... -
Improving Levodopa Delivery, 2012Enhanced Dopamine Availability, Prolonged Activity and Improved Dyskinesia Profile After Administration of Selectively Deuterated Levodopa
Objective/Rationale:
To confirm the found beneficial effects of DP-102 (reduced dyskinetic effects at motoric equieffective doses in comparison to regular levodopa) in a pre-clinical model of Parkinson... -
LRRK2 Biology LEAPS, 2012Combining Mass Spectrometry with Genetic and Pharmacological Approaches to Discover and Validate LRRK2 Substrates
Objective/Rationale:
Much recent work has suggested that comprehending the biological properties of an enzyme termed LRRK2 that is mutated in about one percent of all Parkinson’s disease patients... -
Rapid Response Innovation Awards, 2012Development of Small Molecule Hepatocyte Growth Factor Mimetics for the Treatment of Parkinson’s Disease
Objective/Rationale:
The goal of this project is to determine the clinical potential of a novel, orally active hepatocyte growth factor mimetic for the prevention and/or treatment of Parkinson’s... -
MJFF Research Grant, 2012Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease
Promising Outcomes of Original Grant:
We hypothesized that Nurr1 could be targeted indirectly with small molecules through other nuclear hormone receptors, and that such compounds would have... -
Rapid Response Innovation Awards, 2012Attenuation of Neuroinflammation by Brain-targeted Liposomal Methylprednisolone (2B3-201) in Two Pre-clinical Models of Parkinson's Disease
Objective/Rationale:
Based on increasing evidence of a chronic, self-sustaining environment of inflammation in the brain – or neuroinflammation – in Parkinson’s disease (PD), the objective of the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.